Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hypoallergenic 6 grass and rye pollen allergoid extract
- Development stage
- Unknown
- Lead developer
- Allergopharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Allergovit is a subcutaneous allergen immunotherapy (SCIT) product developed by Allergopharma Joachim Ganzer KG. It consists of a hypoallergenic allergoid extract derived from a mixture of six grass pollen species (*Holcus lanatus*, *Dactylis glomerata*, *Lolium perenne*, *Phleum pratense*, *Poa pratensis*, and *Festuca pratensis*) and rye pollen (*Secale cereale*). The allergens are chemically modified with formaldehyde to reduce their IgE-binding capacity (allergenicity) while preserving their ability to induce a protective immune response (immunogenicity). The extract is co-precipitated with aluminium hydroxide, which acts as an adjuvant to provide a depot effect for sustained release. It is indicated for the treatment of IgE-mediated allergic rhinitis, allergic conjunctivitis, and allergic asthma induced by grass and rye pollen, typically administered in a preseasonal regimen to induce immune tolerance.
- Brand names
- Allergovit
- Other names
- 6-grass plus rye pollen allergoidAllergovit 6-grass/rye
02
Targets
HLA-DR (Human leukocyte antigen DR)Allergen-specific IgE antibodies to grass pollen allergensIgE (Immunoglobulin E)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on hypoallergenic 6 grass and rye pollen allergoid extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hypoallergenic 6 grass and rye pollen allergoid extract.